Skip to main content

Advertisement

SpringerLink
Log in

Somatostatin receptor imaging for neuroendocrine tumors

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Tumors and metastases that express the somatostatin receptor subtypes sst2 sst3 or sst5 can be visualized in vivo after injection of radiolabeled octapeptide somatostatin analogs, like 111In-pentetreotide. 111In-pentetreotide scintigraphy also allows for more accurate staging of the disease by demonstrating tumor sites, which were not shown by conventional imaging. 111In-pentetreotide scintigraphy may also detect resectable tumors that would have remained unrecognized using conventional radiological imaging techniques; it may prevent surgery with curative intent in those patients whose tumors have metastasized to a greater extend than could be detected with conventional radiological imaging and it may be used to select patients for treatment with the currently available octapeptide somatostatin analogs or with tumor targeted radioactive treatment with radiolabelled somatostatin analogs.

111In-pentetreotide scintigraphy has also been used to select patients with pituitary tumors for medical treatment with octapeptide analogs, but its clinical usefulness for this purpose seems to be limited. It further allows scar tissue to be differentiated from tumor recurrence after the pituitary surgery or radiotherapy. However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by 111In-pentetreotide scintigraphy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389–427

    Article  PubMed  CAS  Google Scholar 

  2. Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28–47

    Article  PubMed  CAS  Google Scholar 

  3. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW (2003) Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10:451–458

    Article  PubMed  CAS  Google Scholar 

  4. Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, Pauwels S, Reubi JC (2005) Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 46(Suppl 1):76S–82S:76S–82S

    PubMed  Google Scholar 

  5. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW (1994) Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 733:416–424

    PubMed  CAS  Google Scholar 

  6. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731

    Article  PubMed  CAS  Google Scholar 

  7. Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246–1249

    Article  PubMed  CAS  Google Scholar 

  8. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244

    Article  PubMed  CAS  Google Scholar 

  9. Hubalewska-Dydejczyk A, Szybinski P, Fross-Baron K, Mikolajczak R, Huszno B, Sowa-Staszczak A (2005) (99m)Tc-EDDA/HYNIC-octreotate—a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur 8:155–156

    PubMed  Google Scholar 

  10. Gabriel M, Muehllechner P, Decristoforo C, von Guggenberg E, Kendler D, Prommegger R, Profanter C, Moncayo R, Virgolini I (2005) 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 49:237–424

    PubMed  CAS  Google Scholar 

  11. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolini I (2005) Image fusion analysis of (99 m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 32:1440–1451

    Article  PubMed  Google Scholar 

  12. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ (2001) Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 42:1134–1138

    PubMed  CAS  Google Scholar 

  13. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B (2005) Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 19:311–324

    Article  PubMed  CAS  Google Scholar 

  14. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E (2001) Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220:373–380

    PubMed  CAS  Google Scholar 

  15. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U (2001) PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42:1053–1056

    PubMed  CAS  Google Scholar 

  16. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, Larson SM (2002) Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147–157

    Article  PubMed  CAS  Google Scholar 

  17. Comaru-Schally AM, Schally AV (2005) A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs. Int J Oncol 26:301–309

    PubMed  CAS  Google Scholar 

  18. Lamberts SW, de Herder WW, Hofland LJ (2002) Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 13:451–457

    Article  PubMed  CAS  Google Scholar 

  19. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC, Lamberts SW (1994) Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing’s syndrome. Digestion 55(Suppl 3):54–59

    PubMed  Google Scholar 

  20. Jamar F, Fiasse R, Leners N, Pauwels S (1995) Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 36:542–549

    PubMed  CAS  Google Scholar 

  21. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458–511

    Article  PubMed  CAS  Google Scholar 

  22. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005) Radiolabeled somatostatin analog [177Lu-DOTA°,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762

    Article  PubMed  CAS  Google Scholar 

  23. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O’Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S–66S

    PubMed  CAS  Google Scholar 

  24. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van De Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ (2001) [123I]Metaiodobenzylguanidine and [111In]Octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685–693

    Article  PubMed  CAS  Google Scholar 

  25. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36:1–6

    PubMed  CAS  Google Scholar 

  26. de Herder WW, Hofland LJ (2004) Somatostatin receptors in pheochromocytoma. Front Horm Res 31:145–154

    PubMed  CAS  Google Scholar 

  27. Kwekkeboom DJ, van Urk H, Pauw BK, Lamberts SW, Kooij PP, Hoogma RP, Krenning EP (1993) Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34:873–878

    PubMed  CAS  Google Scholar 

  28. Berna L, Chico A, Matias-Guiu X, Mato E, Catafau A, Alonso C, Mora J, Mauricio D, Rodriguez-Espinosa J, Mari C, Flotats A, Martin JC, Estorch M, Carrio I (1998) Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 25:1482–1488

    Article  PubMed  CAS  Google Scholar 

  29. Berna L, Cabezas R, Mora J, Torres G, Estorch M, Carrio I (1995) 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 144:339–345

    PubMed  CAS  Google Scholar 

  30. Gotthardt M, Battmann A, Hoffken H, Schurrat T, Pollum H, Beuter D, Gratz S, Behe M, Bauhofer A, Klose KJ, Behr TM (2004) 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 25:439–443

    Article  PubMed  CAS  Google Scholar 

  31. de Herder WW, Lamberts SW (2005) Somatostatin analogs as radiodiagnostic tools. Rev Endocr Metab Disord 6:23–27

    Article  PubMed  Google Scholar 

  32. Kwekkeboom DJ, de Herder WW, Krenning EP (1999) Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 22:80–88

    PubMed  CAS  Google Scholar 

  33. Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro LE, Parenti G, Canapicchi R, Bianchi R (1995) [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 39:90–93

    PubMed  CAS  Google Scholar 

  34. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356–2362

    Article  PubMed  CAS  Google Scholar 

  35. Duet M, Ajzenberg C, Benelhadj S, Lajeunie E, Lormeau B, Guillausseau PJ, Rohmer V, Vilain D, Mundler O, Warnet A (1999) Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo. J Nucl Med 40:1252–1256

    PubMed  CAS  Google Scholar 

  36. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136:369–376

    PubMed  CAS  Google Scholar 

  37. de Herder WW, Kwekkeboom DJ, Reijs AEM et al (1996) Receptor scintigraphy with somatostatin analogues and dopamine antagonists of pituitary tumours. In: Von Werder K, Fahlbusch R (eds) Pituitary adenomas. From basic research to diagnosis and therapy. Elsevier Science BV, Amsterdam, pp 93–104

    Google Scholar 

  38. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M (1997) Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 24:728–731

    PubMed  CAS  Google Scholar 

  39. Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM, Ramirez A, Ortega S, Sabatel G, Ramos C, Riva-Aguilar A (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78:110–115

    Article  PubMed  CAS  Google Scholar 

  40. de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, Oei HY, Pols HA, Bruining HA, Nobels FR (1994) Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing’s syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 96:305–312

    Article  PubMed  CAS  Google Scholar 

  41. Weiss M, Yellin A, Husza’r M, Eisenstein Z, Bar-Ziv J, Krausz Y (1994) Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin-receptor scintigraphy. Ann Intern Med 121:198–199

    PubMed  CAS  Google Scholar 

  42. Phlipponneau M, Nocaudie M, Epelbaum J, de Keyzer Y, Lalau JD, Marchandise X, Bertagna X (1994) Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 78:20–24

    Article  PubMed  CAS  Google Scholar 

  43. Lefebvre H, Jegou S, Leroux P, Dero M, Vaudry H, Kuhn JM (1995) Characterization of the somatostatin receptor subtype in a bronchial carcinoid tumor responsible for Cushing’s syndrome. J Clin Endocrinol Metab 80:1423–1428

    Article  PubMed  CAS  Google Scholar 

  44. Matte J, Roufosse F, Rocmans P, Schoutens A, Jacobovitz D, Mockel J (1998) Ectopic Cushing’s syndrome and pulmonary carcinoid tumour identified by [111In-DTPA-D-Phe1]octreotide. Postgrad Med J 74:108–110

    Article  PubMed  CAS  Google Scholar 

  45. Tremble JM, Buxton-Thomas M, Hopkins D, Kane P, Bailey D, Harris PE (2000) Cushing’s syndrome associated with a chemodectoma and a carcinoid tumour. Clin Endocrinol (Oxf) 52:789–793

    Article  CAS  Google Scholar 

  46. Bakalakos EA, Cawley K, O’Dorisio TM, Heck C, Schirmer WJ (1998) Localization of ectopic corticotropin-producing carcinoid tumor with use of indium-111 pentetreotide scintigraphy. Endocr Pract 4:378–381

    PubMed  CAS  Google Scholar 

  47. Tsagarakis S, Christoforaki M, Giannopoulou H, Rondogianni F, Housianakou I, Malagari C, Rontogianni D, Bellenis I, Thalassinos N (2003) A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing’s syndrome. J Clin Endocrinol Metab 88:4754–4758

    Article  PubMed  CAS  Google Scholar 

  48. Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, Catargi B, Roger P, Laurent F (1999) Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84:1193–1202

    Article  PubMed  CAS  Google Scholar 

  49. de Herder WW, Lamberts SW (1999) Octapeptide somatostatin-analogue therapy of Cushing’s syndrome. Postgrad Med J 75:65–66

    PubMed  CAS  Google Scholar 

  50. Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK (2004) The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab 89:2214–2221

    Article  PubMed  CAS  Google Scholar 

  51. Yu J, Koch CA, Patsalides A, Chang R, Altemus RM, Nieman LK, Pacak K (2004) Ectopic Cushing’s syndrome caused by an esthesioneuroblastoma. Endocr Pract 10:119–124

    PubMed  Google Scholar 

  52. Jansson JO, Svensson J, Bengtsson BA, Frohman LA, Ahlman H, Wangberg B, Nilsson O, Nilsson M (1998) Acromegaly and Cushing’s syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin Endocrinol (Oxf) 48:243–250

    CAS  Google Scholar 

  53. Greenman Y, Woolf P, Coniglio J, O’Mara R, Pei L, Said JW, Melmed S (1996) Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. J Clin Endocrinol Metab 81:1628–1633

    Article  PubMed  CAS  Google Scholar 

  54. Moulik PK, Varma TR, Vora JP, Vinjamuri S (2002) The role of somatostatin receptor scintigraphy in the management of pituitary tumours. Nucl Med Commun 23:117–120

    Article  PubMed  CAS  Google Scholar 

  55. Lauriero F, Pierangeli E, Rubini G, Resta M, D’Addabbo A (1998) Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues. Nucl Med Commun 19:1127–1134

    Article  PubMed  CAS  Google Scholar 

  56. Luyken C, Hildebrandt G, Krisch B, Scheidhauer K, Klug N (1996) Clinical relevance of somatostatin receptor scintigraphy in patients with skull base tumours. Acta Neurochir Suppl (Wien) 65:102–104

    CAS  Google Scholar 

  57. Maini CL, Sciuto R, Tofani A, Ferraironi A, Carapella CM, Occhipinti E, Mottolese M, Crecco M (1995) Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nucl Med Commun 16:756–766

    Article  PubMed  CAS  Google Scholar 

  58. Scheidhauer K, Hildebrandt G, Luyken C, Schomacker K, Klug N, Schicha H (1993) Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab Res Suppl 27:59–62

    PubMed  CAS  Google Scholar 

  59. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675–686

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, the Netherlands

    Wouter W. de Herder, Richard A. Feelders, Maarten O. van Aken, Steven W. J. Lamberts & Aart-Jan van der Lely

  2. Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands

    Dik J. Kwekkeboom & Eric P. Krenning

Authors
  1. Wouter W. de Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dik J. Kwekkeboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard A. Feelders
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maarten O. van Aken
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven W. J. Lamberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aart-Jan van der Lely
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eric P. Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wouter W. de Herder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Herder, W.W., Kwekkeboom, D.J., Feelders, R.A. et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 9, 243–248 (2006). https://doi.org/10.1007/s11102-006-0270-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-006-0270-5

Keywords

Search

Navigation